Base de dados : MEDLINE
Pesquisa : D02.355.291.308 [Categoria DeCS]
Referências encontradas : 961 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 97 ir para página                         

  1 / 961 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29354835
[Au] Autor:Avilés-Moreno JR; Berden G; Oomens J; Martínez-Haya B
[Ad] Endereço:Department of Physical, Chemical and Natural Systems, Universidad Pablo de Olavide, E-41013 Seville, Spain. bmarhay@upo.es.
[Ti] Título:Guanidinium/ammonium competition and proton transfer in the interaction of the amino acid arginine with the tetracarboxylic 18-crown-6 ionophore.
[So] Source:Phys Chem Chem Phys;20(6):4067-4073, 2018 Feb 07.
[Is] ISSN:1463-9084
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The recognition of arginine plays a central role in modern proteomics and genomics. Arginine is unique among natural amino acids due to the high basicity of its guanidinium side chain, which sustains specific interactions and proton exchange biochemical processes. The search for suitable macrocyclic ionophores constitutes a promising route towards the development of arginine receptors. This study evaluates the conformational features involved in the binding of free arginine by the polyether macrocycle (18-crown-6)-tetracarboxylic acid. Infrared action vibrational spectroscopy and quantum-chemical computations are combined to characterize the complexes with net charges +1 and +2. The spectrum of the +1 complex can be explained in terms of a configuration predominantly stabilized by a robust bidentate coordination of guanidinium with a carboxylate group formed from the deprotonation of one side group of the crown ether. The released proton is transferred to the amino terminus of arginine, which then coordinates with the crown ether ring. In an alternative type of conformation, partly consistent with experiment, the amino terminus is neutral and the guanidinium group inserts into the crown ether cavity. In the +2 complexes, arginine is always doubly protonated and the most stable conformations are characterized by a tripodal coordination of the ammonium -NH group of arginine with the oxygen atoms of the macrocycle ring, while the interactions of the amino acid with the side carboxylic acid groups of the crown ether acquire a remarkable lesser role.
[Mh] Termos MeSH primário: Compostos de Amônio/química
Arginina/química
Éteres de Coroa/química
Guanidina/química
[Mh] Termos MeSH secundário: Prótons
Teoria Quântica
Espectrofotometria Infravermelho
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ammonium Compounds); 0 (Crown Ethers); 0 (Protons); 63J177NC5B (18-crown-6); 94ZLA3W45F (Arginine); JU58VJ6Y3B (Guanidine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180123
[St] Status:MEDLINE
[do] DOI:10.1039/c7cp07975c


  2 / 961 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28462807
[Au] Autor:Zhang Y; Zhang Z; Huang X; Kang S; Chen G; Wu M; Miao S; Huang Y; Zhao H; Zhang L
[Ad] Endereço:Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
[Ti] Título:Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
[So] Source:Clin Lung Cancer;18(5):e333-e340, 2017 Sep.
[Is] ISSN:1938-0690
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Five major first- and second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, icotinib, afatinib, and dacomitinib, are currently optional for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, there was no head-to-head-based network meta-analysis among all the TKIs in EGFR-mutated populations. METHODS: Eligible literature was searched from an electronic database. Data of objective response rate, disease control rate, progression-free survival, and overall survival were extracted from enrolled studies. Multiple treatment comparisons based on Bayesian network integrated the efficacy of all included treatments. RESULTS: Six phase III randomized trials involving 1055 EGFR-mutated patients with advanced NSCLC were enrolled. Multiple treatment comparisons showed that 5 different EGFR-TKIs shared equivalent therapeutic efficacy in terms of all outcome measures. Rank probabilities indicated that dacomitinib and afatinib had potentially better efficacy compared with erlotinib, gefitinib, and icotinib in the EGFR-mutated patients. When compared with other agents, potential survival benefits (progression-free and overall survival) were observed in dacomitinib, whereas afatinib showed a better rank probability in overall response rate and disease control rate. CONCLUSION: Our study indicated a preferable therapeutic efficacy in the second-generation TKIs (dacomitinib and afatinib) when compared with the first-generation TKIs (erlotinib, gefitinib, and icotinib).
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Neoplasias Pulmonares/tratamento farmacológico
Inibidores de Proteínas Quinases/uso terapêutico
Receptor do Fator de Crescimento Epidérmico/antagonistas & inibidores
[Mh] Termos MeSH secundário: Carcinoma Pulmonar de Células não Pequenas/metabolismo
Ensaios Clínicos Fase III como Assunto
Éteres de Coroa/uso terapêutico
Intervalo Livre de Doença
Cloridrato de Erlotinib/uso terapêutico
Seres Humanos
Neoplasias Pulmonares/metabolismo
Metanálise em Rede
Quinazolinas/uso terapêutico
Quinazolinonas/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Taxa de Sobrevida
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Crown Ethers); 0 (PF 00299804); 0 (Protein Kinase Inhibitors); 0 (Quinazolines); 0 (Quinazolinones); 41UD74L59M (afatinib); 9G6U5L461Q (icotinib); DA87705X9K (Erlotinib Hydrochloride); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); S65743JHBS (gefitinib)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  3 / 961 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28816950
[Au] Autor:Xu T; Wu H; Jin S; Min H; Zhang Z; Shu Y; Wen W; Guo R
[Ad] Endereço:aDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University bCancer Center of Nanjing Medical University cDepartment of Geriatrics dDepartment of Pathology eDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, PR China.
[Ti] Título:Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
[So] Source:Medicine (Baltimore);96(33):e7732, 2017 Aug.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Tyrosine kinase inhibitors (TKIs) are known to have greater efficacy in epidermal growth factor receptor (EGFR) mutation nonsmall cell lung cancer (NSCLC). However, about 10% of EGFR wild-type (wt) patients respond to TKIs. PATIENT CONCERNS: Several strategies to increase the efficacy of TKIs in wt NSCLC are the subjects of ongoing investigations. One of them is combining EGFR TKI with intercalated chemotherapy. DIAGNOSES: We describe a patient with EGFR wt NSCLC, who was found with ovarian and lung metastasis, was treated with pemetrexed and intercalated icotinib. INTERVENTIONS: In this case, we reported the successful long-term maintenance treatment of a patient with EGFR wt NSCLC with pemetrexed and Icotinib. The patient (40-year-old female) was found with ovarian masses and lung masses. Pathological, immunohistochemical, and amplification refractory mutation system (ARMS) assay examinations of ovarian specimen suggested the expression of metastatic lung adenocarcinoma with wt EGFR. After failure treatment with paclitaxel-carboplatin, the patient received 4 cycles of pemetrexed plus platinum with intercalated icotinib and then remained on pemetrexed and icotinib. OUTCOMES: A partial response was achieved after the treatment. The patient's condition had remained stable on pemetrexed and icotinib for more than 20 months, with no evidence of progression. LESSONS: To our knowledge, this is the first report using the long-term maintenance treatment with pemetrexed and intercalated icotinib in EGFR wt patient. The therapeutic strategies warrant further exploration in selected populations of NSCLC.
[Mh] Termos MeSH primário: Adenocarcinoma/tratamento farmacológico
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Neoplasias Pulmonares/tratamento farmacológico
Receptor do Fator de Crescimento Epidérmico/genética
[Mh] Termos MeSH secundário: Adenocarcinoma/genética
Adenocarcinoma/patologia
Adulto
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Carboplatina/uso terapêutico
Carcinoma Pulmonar de Células não Pequenas/genética
Carcinoma Pulmonar de Células não Pequenas/patologia
Éteres de Coroa/uso terapêutico
Progressão da Doença
Feminino
Seres Humanos
Neoplasias Pulmonares/genética
Neoplasias Pulmonares/patologia
Neoplasias Ovarianas/secundário
Pemetrexede/uso terapêutico
Proteínas Tirosina Quinases/antagonistas & inibidores
Quinazolinas/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Crown Ethers); 0 (Quinazolines); 04Q9AIZ7NO (Pemetrexed); 9G6U5L461Q (icotinib); BG3F62OND5 (Carboplatin); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Protein-Tyrosine Kinases); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007732


  4 / 961 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28390943
[Au] Autor:Kuwabara T; Abe K
[Ad] Endereço:Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, 4 Takeda, Kofu 400-8511, Japan. Electronic address: kuwabara@yamanashi.ac.jp.
[Ti] Título:Synthesis and unusual response to potassium of bipyridinium-benzocrown ether conjugate.
[So] Source:Bioorg Med Chem Lett;27(10):2083-2086, 2017 05 15.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A bipyridinium derivative appending a benzocrown ether, in which the phenyl unit in the benzocrown ether was directly bounded to the N-position of the bipyridinium unit, has been synthesized. The compound showed a yellow color associated with an intramolecular charge transfer (CT), which was affected by the presence of alkali and alkaline earth metal ions. An unusual CT response to K for 1 was observed and could be applicable for K sensing.
[Mh] Termos MeSH primário: Éteres de Coroa/química
Potássio/química
Compostos de Piridínio/química
[Mh] Termos MeSH secundário: Íons/química
Lítio/química
Espectroscopia de Ressonância Magnética
Espectrometria de Massas por Ionização por Electrospray
Espectrofotometria
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Crown Ethers); 0 (Ions); 0 (Pyridinium Compounds); 9FN79X2M3F (Lithium); RWP5GA015D (Potassium)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171124
[Lr] Data última revisão:
171124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE


  5 / 961 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28219203
[Au] Autor:Yuan DM; Song Y
[Ad] Endereço:Department of Respiratory Medicine, Jinling Hospital, Nanjing University Institute of Respiratory Medicine, Nanjing 210002, China.
[Ti] Título:[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].
[So] Source:Zhonghua Zhong Liu Za Zhi;39(2):98-101, 2017 Feb 23.
[Is] ISSN:0253-3766
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have become the preferred treatment option for advanced non-small-cell lung cancer (NSCLC) patients with activating mutations in epidermal growth factor receptor (EGFR) according to major practice guidelines. Gefitinib, elortinib and icotinib formed the cornerstone of first-line EGFR-TKIs in the clinical practice in our country. Now, with the continuously emerging of new types of EGFR-TKIs and ever-increasing publication of clinical trial results on afatinib, AZD9291 and other TKIs, we have more first-line choices for patients with EGFR mutations. Meanwhile, the development of gene detection technology is facilitating investigators to get insights on the molecular biological behavior of NSCLC and to elucidate the mechanism of drug resistance. This review will focus on precision first-line therapy for advanced NSCLC patients harboring EGFR mutation.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Neoplasias Pulmonares/tratamento farmacológico
Inibidores de Proteínas Quinases/uso terapêutico
Receptor do Fator de Crescimento Epidérmico/antagonistas & inibidores
[Mh] Termos MeSH secundário: Carcinoma Pulmonar de Células não Pequenas/genética
Éteres de Coroa/uso terapêutico
Genes erbB-1
Seres Humanos
Neoplasias Pulmonares/genética
Mutação
Quinazolinas/uso terapêutico
Receptor do Fator de Crescimento Epidérmico/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Crown Ethers); 0 (Protein Kinase Inhibitors); 0 (Quinazolines); 41UD74L59M (afatinib); 9G6U5L461Q (icotinib); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); S65743JHBS (gefitinib)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170801
[Lr] Data última revisão:
170801
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0253-3766.2017.02.005


  6 / 961 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28165562
[Au] Autor:Ma XH; Tian TD; Liu HM; Li QJ; Gao QL; Li L; Shi B
[Ad] Endereço:Integrated TCM & Western Medicine Department, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China. tdtian@tom.com.
[Ti] Título:Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.
[So] Source:Eur Rev Med Pharmacol Sci;21(2):266-274, 2017 01.
[Is] ISSN:2284-0729
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the efficacy and safety of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and discuss the influence factors on efficacy. PATIENTS AND METHODS: 120 treatment-experienced patients confirmed by pathology or cytology with stage III B-IV non-small cell lung cancer took icotinib hydrochloride and erlotinib orally until the occurrence of disease progression or serious adverse reactions. Then, the efficacy of icotinib hydrochloride and the related influence factors were analyzed. RESULTS: In icotinib hydrochloride group, the response rate and the disease control rate were 30.00% and 65.00%, and the median progression-free survival time was 179 days (95% CI: 103.21-254.78); in erlotinib group, the response rate and the disease control rate were 25.00% and 56.70%, and the median progression-free survival time was 121 days (95% CI: 95.05-146.94). Moreover, the objective response rate and the disease control rate of second-line therapy were both superior to the third-line and above therapy. The objective response rate of patients with complete response/partial response/stable disease after the first-line therapy was higher than that of patients without response after the first-line therapy (p<0.05), and the significant differences existed in the objective response rate and the disease control rate among mutant group, wild-type group, and unknown group (p<0.05). The response rate and the disease control rate of erythra group were higher than those of non-erythra group (p<0.05). It was showed in the univariate analysis that the progression-free survival was correlated with the smoking status and the epidermal growth factor receptor gene mutations. CONCLUSIONS: The icotinib hydrochloride is effective and safe in treating the treatment-experienced patients with advanced NSCLC, especially for patients with sensitive mutations.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Éteres de Coroa/uso terapêutico
Neoplasias Pulmonares/tratamento farmacológico
Quinazolinas/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Intervalo Livre de Doença
Feminino
Seres Humanos
Masculino
Meia-Idade
Mutação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Crown Ethers); 0 (Quinazolines); 9G6U5L461Q (icotinib)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE


  7 / 961 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28125069
[Au] Autor:Wong JK; Todd MH; Rutledge PJ
[Ad] Endereço:School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia. joseph.wong@sydney.edu.au.
[Ti] Título:Recent Advances in Macrocyclic Fluorescent Probes for Ion Sensing.
[So] Source:Molecules;22(2), 2017 Jan 25.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Small-molecule fluorescent probes play a myriad of important roles in chemical sensing. Many such systems incorporating a receptor component designed to recognise and bind a specific analyte, and a reporter or transducer component which signals the binding event with a change in fluorescence output have been developed. Fluorescent probes use a variety of mechanisms to transmit the binding event to the reporter unit, including photoinduced electron transfer (PET), charge transfer (CT), Förster resonance energy transfer (FRET), excimer formation, and aggregation induced emission (AIE) or aggregation caused quenching (ACQ). These systems respond to a wide array of potential analytes including protons, metal cations, anions, carbohydrates, and other biomolecules. This review surveys important new fluorescence-based probes for these and other analytes that have been reported over the past five years, focusing on the most widely exploited macrocyclic recognition components, those based on cyclam, calixarenes, cyclodextrins and crown ethers; other macrocyclic and non-macrocyclic receptors are also discussed.
[Mh] Termos MeSH primário: Técnicas Biossensoriais
Corantes Fluorescentes/química
Íons/química
Compostos Macrocíclicos/química
[Mh] Termos MeSH secundário: Éteres de Coroa/química
Ciclodextrinas/química
Compostos Heterocíclicos/química
Pontos Quânticos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Crown Ethers); 0 (Cyclodextrins); 0 (Fluorescent Dyes); 0 (Heterocyclic Compounds); 0 (Ions); 0 (Macrocyclic Compounds); 295-37-4 (cyclam)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170509
[Lr] Data última revisão:
170509
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170127
[St] Status:MEDLINE


  8 / 961 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28056322
[Au] Autor:Chen H; Wang HP; Zhang L; Si XY
[Ad] Endereço:Department of Respiration, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
[Ti] Título:[The therapeutic value and safety of icotinib as first-line therapy for advanced non-small cell lung cancer patients].
[So] Source:Zhonghua Nei Ke Za Zhi;56(1):39-43, 2017 Jan 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To evaluate the safety and efficacy of icotinib as first-line therapy in Chinese non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) sensitive mutations. Patients with stage â…¢B/â…£ NSCLC who had EGFR sensitive mutation and had no previous treatment were enrolled into this study. The response rates, progress free survival (PFS), overall survival (OS), and the safety were analyzed. Ninety advanced adenocarcinoma patients were enrolled in this study, 44 patients had partial response (PR), 42 patients had stable disease (SD), 4 patients had progressive disease (PD), with an overall response rate (ORR) of 48.9%, and a disease control rate (DCR) of 95.6%. The median PFS was 14.9 months (95% 13.5-16.3) and the OS was 37.0 weeks (95% 27.9-46.1). Patients with brain metastases showed higher ORR( =0.049). Patients with stage â…¢B had longer PFS than those with stage â…£( =0.007). The most common adverse events were grade 1-2 skin rash (38 patients, 40.9%). Other adverse events included dry skin, oral mucositis, diarrhea and liver function injury. Three patients withdrew because of severe liver injury or skin rash. No treatment related mortality occurred. Icotinib is effective and safe as first-line treatment for Chinese advanced NSCLC patients with EGFR sensitive mutation.
[Mh] Termos MeSH primário: Adenocarcinoma/tratamento farmacológico
Grupo com Ancestrais do Continente Asiático/estatística & dados numéricos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Éteres de Coroa/administração & dosagem
Neoplasias Pulmonares/tratamento farmacológico
Quinazolinas/administração & dosagem
Receptor do Fator de Crescimento Epidérmico/genética
[Mh] Termos MeSH secundário: Adenocarcinoma/mortalidade
Adenocarcinoma/patologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/administração & dosagem
Grupo com Ancestrais do Continente Asiático/genética
Carcinoma Pulmonar de Células não Pequenas/genética
Carcinoma Pulmonar de Células não Pequenas/metabolismo
Carcinoma Pulmonar de Células não Pequenas/mortalidade
China
Éteres de Coroa/uso terapêutico
Intervalo Livre de Doença
Feminino
Seres Humanos
Neoplasias Pulmonares/genética
Neoplasias Pulmonares/metabolismo
Neoplasias Pulmonares/mortalidade
Masculino
Meia-Idade
Mutação
Estadiamento de Neoplasias
Quinazolinas/uso terapêutico
Receptor do Fator de Crescimento Epidérmico/metabolismo
Segurança
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Crown Ethers); 0 (Quinazolines); 9G6U5L461Q (icotinib); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170106
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2017.01.010


  9 / 961 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28012588
[Au] Autor:Parchami R; Kamalabadi M; Alizadeh N
[Ad] Endereço:Department of Chemistry, Faculty of Sciences, Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran.
[Ti] Título:Determination of biogenic amines in canned fish samples using head-space solid phase microextraction based on nanostructured polypyrrole fiber coupled to modified ionization region ion mobility spectrometry.
[So] Source:J Chromatogr A;1481:37-43, 2017 Jan 20.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The head-space solid phase microextraction (HS-SPME) was applied to extraction and determination of histamine (HIS), putrescine (PUT), cadaverine (CAD), tyramine (TYR) in canned fish samples by ion mobility spectrometry (IMS) without any derivatization process. HIS and CAD have the same mobilities in nitrogen as buffer gas and their corresponding peaks are severely overlapped in ion mobility spectrum. Peak separation was acquired in the presence of 18-crown-6 vapor as complexation reagent into carrier gas and modified ionization region of IMS (MIR-IMS) at optimum flow rate. The interaction between 18-crown-6 and the mentioned amines forms nanocluster product ions with different cross section areas and ion mobilities. The effects of main extraction parameters on the efficiency of HS-SPME-MIR-IMS were investigated and optimized. Relative standard deviations (RSD%) of the biogenic amines determination at 50µgL concentration level were obtained in range 5.7%-6.3%. Limits of detection for analytes were in the range of 0.6-1ngg . HS-SPME-MIR-IMS results indicate that the proposed method can be successfully used in biogenic amines analysis in water and food samples. Method validation was conducted by comparing our results with those obtained through GC-MS method.
[Mh] Termos MeSH primário: Aminas Biogênicas/análise
Produtos Pesqueiros/análise
Nanoestruturas/química
Polímeros/química
Pirróis/química
Microextração em Fase Sólida/métodos
Análise Espectral/métodos
[Mh] Termos MeSH secundário: Tampões (Química)
Éteres de Coroa/química
Cromatografia Gasosa-Espectrometria de Massas
Concentração de Íons de Hidrogênio
Íons
Nitrogênio/química
Reprodutibilidade dos Testes
Sais/química
Temperatura Ambiente
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biogenic Amines); 0 (Buffers); 0 (Crown Ethers); 0 (Ions); 0 (Polymers); 0 (Pyrroles); 0 (Salts); 30604-81-0 (polypyrrole); 63J177NC5B (18-crown-6); N762921K75 (Nitrogen)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161226
[St] Status:MEDLINE


  10 / 961 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28000387
[Au] Autor:Wang W; Song Z; Zhang Y
[Ad] Endereço:Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
[Ti] Título:A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
[So] Source:Cancer Med;6(1):154-162, 2017 Jan.
[Is] ISSN:2045-7634
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A sensitive and convenient method for detecting epidermal growth factor receptor (EGFR) T790M mutations from circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI resistance would be desirable to direct patient sequential treatment strategy. A comparison of two platforms for detecting EGFR mutations in plasma ctDNA was undertaken. Plasma samples and tumor samples were collected from patients with acquired EGFR-TKI resistance in Zhejiang Cancer Hospital from December 2014 to December 2015. Extracted ctDNA was analyzed using two platforms (Droplet Digital PCR and ARMS [dPCR]). A total of 108 patients were enrolled in this study. One hundred and eight patient plasma samples were detected by ddPCR and 75 were detected by ARMS. And 16 patients obtained tissue re-biopsy, using ARMS assay for detecting EGFR T790M mutation. In all, 43.7% (47/108) had acquired T790M mutation by ddPCR. In 75 patient plasma samples, comparing ddPCR with ARMS, the rates of T790M mutation were 46.7% (35/75) and 25.3% (19/75) by ddPCR and ARMS, respectively. Of all, 16 patients both had tumor and plasma samples, the T790M mutation rates were 56.3% (9/16) by ARMS in tissue and 50.5% (8/16) by ddPCR in plasma ctDNA. The progression mode tended to gradual progression in T790M mutation patients (40.4%), but the T790M negative was inclined to the mode of dramatic progression (39.3%). The patients with T790M-positive tumors had a longer time to disease progression after treatment with EGFR-TKIs (median, 13.1 months vs. 10.8 months; P = 0.010) and overall survival (median, 35.3 months vs. 30.3 months; P = 0.214) compared with those with T790M-negative patients. Our study demonstrates ddPCR assay may provide a highly sensitive method to detect EGFR T790M gene in plasma. And T790M-positive patients have better clinical outcomes to EGFR-TKIs than T790M-negative patients.
[Mh] Termos MeSH primário: Carcinoma Pulmonar de Células não Pequenas/genética
Resistência a Medicamentos Antineoplásicos
Neoplasias Pulmonares/genética
Mutação
Reação em Cadeia da Polimerase/métodos
Receptor do Fator de Crescimento Epidérmico/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Carcinoma Pulmonar de Células não Pequenas/sangue
Carcinoma Pulmonar de Células não Pequenas/patologia
Éteres de Coroa/uso terapêutico
DNA de Neoplasias/sangue
Cloridrato de Erlotinib/uso terapêutico
Feminino
Seres Humanos
Neoplasias Pulmonares/sangue
Neoplasias Pulmonares/patologia
Masculino
Meia-Idade
Medicina de Precisão
Prognóstico
Quinazolinas/uso terapêutico
Kit de Reagentes para Diagnóstico
Receptor do Fator de Crescimento Epidérmico/sangue
Sensibilidade e Especificidade
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Crown Ethers); 0 (DNA, Neoplasm); 0 (Quinazolines); 0 (Reagent Kits, Diagnostic); 9G6U5L461Q (icotinib); DA87705X9K (Erlotinib Hydrochloride); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); S65743JHBS (gefitinib)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.1002/cam4.978



página 1 de 97 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde